Article
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.
Nature communications - 7 Jan 2026
Singh Pratishtha, D'Rozario Ranit, Chakraborty Bidisha, Meher Swadhin, Raychaudhuri Deblina, Tannir Aminah J, Li Yang, Majumdar Anurag, Hawkins Jessalyn, Xiong Yun, Lorenzi Philip, Sharma Padmanee, Akdemir Kadir, Pilie Patrick, Jain Abhinav K, Lee Byron Hing Lung, Goswami Sangeeta
Abstract excerpt
Mutations in epigenetic regulators are common in bladder cancer, yet their impact on therapeutic responses remains unclear. Here, we identify that loss-of-function mutations in KDM6A, a histone demethylase altered in about 26% of advanced bladder cancers, are associated with poor survival after cisplatin chemotherapy, whereas they correlate with improved outcomes with anti-PD-1 therapy. Using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.